Retour

Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Management Directors and Officers

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company’s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM solution to the global market.

GlobeNewswire Inc. • 08/05/2024 à 16:36:00
Trinity Biotech plc
Website: https://www.trinitybiotech.com
Status: Active
Company Info

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

List Date1995-08-18
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeADRC
Currency NameUSD
CIK0000888721
Composite figiBBG000C1D008
Share Class figiBBG001S67CN4
Market Cap14,955,512 USD
Total Employees380
Share Class Shares Outstanding188830000
Weighted Shares Outstanding9465514
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
1.579
1.596
1.521
1.525
1.58
Variance
-0.88%
4.52%
-0.07%
-3.48%
-6.95%
Open
1.593
1.527
1.522
1.58
1.698
Highest
1.62
1.804
1.535
1.63
1.992
Lowest
1.62
1.65
1.535
1.63
1.925
History
PeriodVarhighestlowest
1 week
-7.01%
1.992
1.535
1 month
-16.98%
1.91
1.535
3 month
162.73%
0.601
0.542
6 month
304.87%
0.41
0.375
1 year
67.98%
0.98
0.37
3 year
-50.66%
3.2999
0.37
5 year
-34.21%
2.69
0.37
10 year
-93.44%
24.41
0.37
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:TRIB240517P00007500 OPASPS Put American 100 7.5 EMLD 2024-05-17
O:TRIB1240517P00007500 OPASPN Put American 20 7.5 GMNI 2024-05-17
O:TRIB1240517P00005000 OPASPN Put American 20 5 GMNI 2024-05-17
O:TRIB1240517P00002500 OPASPN Put American 20 2.5 GMNI 2024-05-17
O:TRIB1240517C00007500 OCASPN Call American 20 7.5 GMNI 2024-05-17
O:TRIB240517P00005000 OPASPS Put American 100 5 EMLD 2024-05-17
O:TRIB1240517C00005000 OCASPN Call American 20 5 GMNI 2024-05-17
O:TRIB1240517C00002500 OCASPN Call American 20 2.5 GMNI 2024-05-17
O:TRIB240517P00002500 OPASPS Put American 100 2.5 EMLD 2024-05-17
O:TRIB240517C00007500 OCASPS Call American 100 7.5 EMLD 2024-05-17
O:TRIB240517C00005000 OCASPS Call American 100 5 EMLD 2024-05-17
O:TRIB240517C00002500 OCASPS Call American 100 2.5 EMLD 2024-05-17
O:TRIB1240419P00007500 OPASPN Put American 20 7.5 GMNI 2024-04-19
O:TRIB1240419P00005000 OPASPN Put American 20 5 GMNI 2024-04-19
O:TRIB240419P00007500 OPASPS Put American 100 7.5 EMLD 2024-04-19
O:TRIB240419P00005000 OPASPS Put American 100 5 EMLD 2024-04-19
O:TRIB1240419P00002500 OPASPN Put American 20 2.5 GMNI 2024-04-19
O:TRIB240419P00002500 OPASPS Put American 100 2.5 EMLD 2024-04-19
O:TRIB240419C00007500 OCASPS Call American 100 7.5 EMLD 2024-04-19
O:TRIB240419C00005000 OCASPS Call American 100 5 EMLD 2024-04-19
O:TRIB240419C00002500 OCASPS Call American 100 2.5 EMLD 2024-04-19
O:TRIB1240419C00007500 OCASPN Call American 20 7.5 GMNI 2024-04-19
O:TRIB1240419C00005000 OCASPN Call American 20 5 GMNI 2024-04-19
O:TRIB1240419C00002500 OCASPN Call American 20 2.5 GMNI 2024-04-19
O:TRIB240315P00007500 OPASPS Put American 100 7.5 EMLD 2024-03-15
O:TRIB240315P00005000 OPASPS Put American 100 5 EMLD 2024-03-15
O:TRIB240315P00002500 OPASPS Put American 100 2.5 EMLD 2024-03-15
O:TRIB240315C00007500 OCASPS Call American 100 7.5 EMLD 2024-03-15
O:TRIB240315C00005000 OCASPS Call American 100 5 EMLD 2024-03-15
O:TRIB240315C00002500 OCASPS Call American 100 2.5 EMLD 2024-03-15
O:TRIB240216P00007500 OPASPS Put American 100 7.5 EMLD 2024-02-16
O:TRIB240216P00005000 OPASPS Put American 100 5 EMLD 2024-02-16
O:TRIB240216P00002500 OPASPS Put American 100 2.5 EMLD 2024-02-16
O:TRIB240216C00007500 OCASPS Call American 100 7.5 EMLD 2024-02-16
O:TRIB240216C00005000 OCASPS Call American 100 5 EMLD 2024-02-16
O:TRIB240216C00002500 OCASPS Call American 100 2.5 EMLD 2024-02-16
O:TRIB240119P00007500 OPASPS Put American 100 7.5 EMLD 2024-01-19
O:TRIB240119P00005000 OPASPS Put American 100 5 EMLD 2024-01-19
O:TRIB240119P00002500 OPASPS Put American 100 2.5 EMLD 2024-01-19
O:TRIB240119C00007500 OCASPS Call American 100 7.5 EMLD 2024-01-19
O:TRIB240119C00005000 OCASPS Call American 100 5 EMLD 2024-01-19
O:TRIB240119C00002500 OCASPS Call American 100 2.5 EMLD 2024-01-19
O:TRIB231215P00007500 OPASPS Put American 100 7.5 EMLD 2023-12-15
O:TRIB231215P00005000 OPASPS Put American 100 5 EMLD 2023-12-15
O:TRIB231215P00002500 OPASPS Put American 100 2.5 EMLD 2023-12-15
O:TRIB231215C00007500 OCASPS Call American 100 7.5 EMLD 2023-12-15
O:TRIB231215C00005000 OCASPS Call American 100 5 EMLD 2023-12-15
O:TRIB231215C00002500 OCASPS Call American 100 2.5 EMLD 2023-12-15
O:TRIB231117P00007500 OPASPS Put American 100 7.5 EMLD 2023-11-17
O:TRIB231117P00005000 OPASPS Put American 100 5 EMLD 2023-11-17
O:TRIB231117P00002500 OPASPS Put American 100 2.5 EMLD 2023-11-17
O:TRIB231117C00007500 OCASPS Call American 100 7.5 EMLD 2023-11-17
O:TRIB231117C00005000 OCASPS Call American 100 5 EMLD 2023-11-17
O:TRIB231117C00002500 OCASPS Call American 100 2.5 EMLD 2023-11-17
O:TRIB231020P00007500 OPASPS Put American 100 7.5 EMLD 2023-10-20
O:TRIB231020P00005000 OPASPS Put American 100 5 EMLD 2023-10-20
O:TRIB231020P00002500 OPASPS Put American 100 2.5 EMLD 2023-10-20
O:TRIB231020C00007500 OCASPS Call American 100 7.5 EMLD 2023-10-20
O:TRIB231020C00005000 OCASPS Call American 100 5 EMLD 2023-10-20
O:TRIB231020C00002500 OCASPS Call American 100 2.5 EMLD 2023-10-20
O:TRIB230915P00007500 OPASPS Put American 100 7.5 EMLD 2023-09-15
O:TRIB230915P00005000 OPASPS Put American 100 5 EMLD 2023-09-15
O:TRIB230915P00002500 OPASPS Put American 100 2.5 EMLD 2023-09-15
O:TRIB230915C00007500 OCASPS Call American 100 7.5 EMLD 2023-09-15
O:TRIB230915C00005000 OCASPS Call American 100 5 EMLD 2023-09-15
O:TRIB230915C00002500 OCASPS Call American 100 2.5 EMLD 2023-09-15
O:TRIB230818P00007500 OPASPS Put American 100 7.5 EMLD 2023-08-18
O:TRIB230818P00005000 OPASPS Put American 100 5 EMLD 2023-08-18
O:TRIB230818P00002500 OPASPS Put American 100 2.5 EMLD 2023-08-18
O:TRIB230818C00007500 OCASPS Call American 100 7.5 EMLD 2023-08-18
O:TRIB230818C00005000 OCASPS Call American 100 5 EMLD 2023-08-18
O:TRIB230818C00002500 OCASPS Call American 100 2.5 EMLD 2023-08-18
News Stream
Management Directors and Officers
Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company’s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM solution to the global market.
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ET Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ET
GlobeNewswire Inc. • 1mo ago
News Product / Services Announcement
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (NASDAQ: TRIB) (the “Company”) today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(a)(1), which requires the Company's American Depositary Shares (“ADSs”) to maintain a minimum bid price of $1.00 per ADS. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed.
GlobeNewswire Inc. • 2mo ago
News Product / Services Announcement
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
DUBLIN, Ireland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depositary shares (“ADSs”) from one (1) ADS representing four (4) Class A ordinary shares to one (1) ADS representing twenty (20) Class A ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Global Market is expected to take place at the open of trading on February 23, 2024 (U.S. Eastern Time) (the “Effective Date”).
GlobeNewswire Inc. • 3mo ago
Stocks Changes in company's own shares
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
DUBLIN, Ireland, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing four (4) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares.
GlobeNewswire Inc. • 3mo ago
Calendar Calendar of Events
Trinity Biotech to Present at Emerging Growth Conference
DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024. The Company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Please see the presentation information below.
GlobeNewswire Inc. • 3mo ago
Management Management statements
Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code
DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.
GlobeNewswire Inc. • 3mo ago
Stocks Earnings Releases and Operating Results
Trinity Biotech Announces Q3 2023 Financial Results & Business Update
-Investor call to be held today at 8:30 am EST -Investor call to be held today at 8:30 am EST
GlobeNewswire Inc. • 3mo ago
Management Partnerships
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India
DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring (“CGM”) biosensor device in China and India. This Letter of Intent is related to the Company’s recently announced acquisition of the CGM assets of Waveform Technologies, Inc.
GlobeNewswire Inc. • 3mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT